Clinical Trial Update: Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating second-line cabozantinib in combination with atezolizumab for recurrent or metastatic esophageal squamous cell carcinoma has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• cabozantinib (cabozantinib)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Esophageal Cancer, Metastatic Cancer | Phase 2 | Status: COMPLETED